Company intelligence / Profile preview

Hebei Newtherapy Bio-Pharma Technology Co., Ltd.

Ownership: Private
Development stage: Phase 1

Overview

The company's lead program involves umbilical cord-derived mesenchymal stem cells for the treatment of Parkinson's disease. A Phase 1 clinical trial was initiated in January 2018 to evaluate safety and efficacy. The current status is unknown/pending with no published results available as of early 2025

Therapeutic areas: EndocrinologyNeurology
Modalities: Mesenchymal stem cell therapy
Industry: Biotech

Drug pipeline

1 asset

MSC therapy

Phase 1

Indications: Parkinson's disease

Beyond the preview

Go deeper on Hebei Newtherapy Bio-Pharma Technology Co., Ltd..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Hebei Newtherapy Bio-Pharma Technology Co., Ltd..

Explore the full profile